Alyeska Investment Group
SAGE

Alyeska Investment Group’s Sage Therapeutics SAGE Stock Holding History

Alyeska Investment Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-528,821
Closed -$10.9M – 645
2023
Q3 		$10.9M Buy
+528,821
New +$15.3M 0.07% 269
2018
Q2 		– Sell
-2,375
Closed -$383K – 513
2018
Q1 		$383K Sell
2,375
-153,254
-98% -$26M ﹤0.01% 419
2017
Q4 		$25.6M Buy
155,629
+44,832
+40% +$4.35M 0.2% 131
2017
Q3 		$6.9M Buy
110,797
+26,348
+31% +$2.07M 0.05% 270
2017
Q2 		$6.73M Buy
84,449
+9,449
+13% +$683K 0.06% 267
2017
Q1 		$5.33M Buy
+75,000
New +$4.39M 0.04% 308
2016
Q2 		– Sell
-78,917
Closed -$2.53M – 488
2016
Q1 		$2.53M Buy
+78,917
New +$2.78M 0.02% 314
2015
Q1 		– Sell
-47,515
Closed -$1.74M – 569
2014
Q4 		$1.74M Sell
47,515
-52,159
-52% -$1.94M 0.03% 352
2014
Q3 		$3.14M Buy
+99,674
New +$2.89M 0.06% 263

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Alyeska Investment Group's SAGE Position: Q4 2023 in Review

Alyeska Investment Group sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 528,821 shares — an estimated $10.9M sold.

Alyeska Investment Group first reported a position in SAGE in Q3 2014 and held it in 9 quarters. The position peaked at $25.6M in Q4 2017. 200 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

  • Alyeska Investment Group reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 528,821 Sage Therapeutics shares in Q4 2023, an estimated $10.9M.
  • Alyeska Investment Group first reported a position in Sage Therapeutics in Q3 2014 and held it in 9 quarters.
  • Alyeska Investment Group's Sage Therapeutics position peaked at $25.6M in Q4 2017.
  • 200 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on Alyeska Investment Group's 13F filing for Q4 2023, filed 14 Feb 2024.